International Patent Application:

Prosemble has filed International Patent Application No. PCT/GB2024/052768 on 31st October 2024, with priority based on US Patent Application No. 63/594633, filed on 31st October 2023.

Protocol and Clinical Trial Requirements:

• Prosemble has developed a comprehensive protocol for nanoparticle protein production, and has successfully completed proof-of-concept biophysical characterisation, demonstrating the structure, assembly, and disassembly of nanoparticles.

• The company is currently advancing the development of an efficient encapsulation and delivery method for doxorubicin in breast cancer treatment.

• In terms of clinical trials, Prosemble plans to conduct a combined Stage 1 and Stage 2 trial, using three innocuous compounds to establish safety and dosage. For anticancer drugs, only Stage 3 trials will be required post these initial stages.

Peer Review and Manuscript:

Prosemble’s manuscript has undergone peer review and has been published in Proceedings of the National Academy of Sciences (PNAS). The manuscript is also accessible on BioRXiv.

In Vivo Mouse Trials:

Ongoing discussions were in place for initiating mouse trials with TransCure BioServices (France) and Sygnature Discovery (UK). The trials commenced with TransCure in December 2024, and full safety results are expected in April 2025. Preliminary safety results have been positive.

AI Advancements:

Prosemble has secured funding from AWS to support AI hosting and engineering capabilities. Moterra has been appointed to facilitate AWS integration, enhancing the company's AI infrastructure.

SEIS Assurance and Due Diligence:

Prosemble has received SEIS assurance, and EG Technology has conducted due diligence on the company’s AI capabilities, further validating its technological advancements.

Collaborations and Partnerships:

Discussions are actively ongoing with the Lady Garden Foundation, centred on the development of targeted drug delivery solutions for five gynaecological cancers. In addition, collaborative talks are in progress with eAltra Limited, SynLaia Innovation, UCL, and Ben-Gurion University of the Negev / Soroka Medical Centre, focusing on lung cancer.

Product Development and Market Strategy:

Prosemble's initial product focuses on breast cancer, specifically the delivery of Doxorubicin. The company plans to target generic drugs for potential partnerships and licensing agreements, with particular emphasis on Doxorubicin, Cisplatin, and Docetaxel. By the end of 2025, Prosemble aims to secure 2-3 partnerships with leading pharmaceutical and biotech companies, as well as develop AI collaborations, potentially extending into FMCG sectors.